Linear IgA bullous dermatosis secondary to drugs: a real-world pharmacovigilance study of the FDA adverse event reporting system

BackgroundLinear IgA bullous dermatosis (LABD) is a rare autoimmune blistering disease. The induction of LABD by medications is a critical issue, with previous studies highlighting the link between specific drugs and the onset of LABD. This study aims to assess the reported associations between LABD...

Full description

Saved in:
Bibliographic Details
Main Authors: Yixuan Yang, Hanzhang Xie, Shuhan Liu, Ying Jia, Bingnan Cui, Zhanshuo Xiao
Format: Article
Language:English
Published: Frontiers Media S.A. 2025-01-01
Series:Frontiers in Medicine
Subjects:
Online Access:https://www.frontiersin.org/articles/10.3389/fmed.2025.1521697/full
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1832590488481300480
author Yixuan Yang
Hanzhang Xie
Shuhan Liu
Ying Jia
Bingnan Cui
Zhanshuo Xiao
author_facet Yixuan Yang
Hanzhang Xie
Shuhan Liu
Ying Jia
Bingnan Cui
Zhanshuo Xiao
author_sort Yixuan Yang
collection DOAJ
description BackgroundLinear IgA bullous dermatosis (LABD) is a rare autoimmune blistering disease. The induction of LABD by medications is a critical issue, with previous studies highlighting the link between specific drugs and the onset of LABD. This study aims to assess the reported associations between LABD and numerous available medications using the FDA adverse event reporting system (FAERS).MethodsThe study encompassed FAERS reports spanning the years 2004–2024. Medical Dictionary for Regulatory Activities (MedDRA) was used to identify cases of LABD. The Reporting Odds Ratio, Proportional Reporting Ratio, Bayesian Confidence Propagation Neural Network, and Empirical Bayes Geometric Mean were calculated to assess the reported associations between available drugs and LABD. A significant statistical association was considered when a drug signal met the criteria of all four algorithms.ResultsIn the FAERS database analysis, we identified 1,394 adverse event (AE) reports associated with LABD. The gender distribution of reports was relatively balanced, with the highest proportion in the 66–85 age group. The United States had the highest number of reports. Vancomycin and Amoxicillin were the most frequently reported drugs, with 559 and 58 reports, respectively. Through disproportionality analysis, we identified 34 drugs significantly associated with AEs of LABD, including antibiotics, antifungal medications, analgesics, nonsteroidal anti-inflammatory drugs, cardiovascular medications, and calcium channel blockers, among which the antibiotic Vancomycin showed the highest association. These results emphasize the need for further clinical attention to the safety of specific medications.ConclusionThis is the first real-world study using the FAERS database to investigate drug-induced LABD. LABD is closely associated with antibiotic medications. Close monitoring of patients is required when these medications are used clinically to promptly detect and manage potential AEs such as LABD.
format Article
id doaj-art-aebebd13a72d4fb291a7f773e36bcd67
institution Kabale University
issn 2296-858X
language English
publishDate 2025-01-01
publisher Frontiers Media S.A.
record_format Article
series Frontiers in Medicine
spelling doaj-art-aebebd13a72d4fb291a7f773e36bcd672025-01-23T15:59:33ZengFrontiers Media S.A.Frontiers in Medicine2296-858X2025-01-011210.3389/fmed.2025.15216971521697Linear IgA bullous dermatosis secondary to drugs: a real-world pharmacovigilance study of the FDA adverse event reporting systemYixuan Yang0Hanzhang Xie1Shuhan Liu2Ying Jia3Bingnan Cui4Zhanshuo Xiao5Department of Dermatology, Guang’anmen Hospital, China Academy of Chinese Medical Sciences, Beijing, ChinaBeijing University of Chinese Medicine, Beijing, ChinaBeijing University of Chinese Medicine, Beijing, ChinaDepartment of Dermatology, Guang’anmen Hospital, China Academy of Chinese Medical Sciences, Beijing, ChinaDepartment of Dermatology, Guang’anmen Hospital, China Academy of Chinese Medical Sciences, Beijing, ChinaDepartment of Dermatology, Guang’anmen Hospital, China Academy of Chinese Medical Sciences, Beijing, ChinaBackgroundLinear IgA bullous dermatosis (LABD) is a rare autoimmune blistering disease. The induction of LABD by medications is a critical issue, with previous studies highlighting the link between specific drugs and the onset of LABD. This study aims to assess the reported associations between LABD and numerous available medications using the FDA adverse event reporting system (FAERS).MethodsThe study encompassed FAERS reports spanning the years 2004–2024. Medical Dictionary for Regulatory Activities (MedDRA) was used to identify cases of LABD. The Reporting Odds Ratio, Proportional Reporting Ratio, Bayesian Confidence Propagation Neural Network, and Empirical Bayes Geometric Mean were calculated to assess the reported associations between available drugs and LABD. A significant statistical association was considered when a drug signal met the criteria of all four algorithms.ResultsIn the FAERS database analysis, we identified 1,394 adverse event (AE) reports associated with LABD. The gender distribution of reports was relatively balanced, with the highest proportion in the 66–85 age group. The United States had the highest number of reports. Vancomycin and Amoxicillin were the most frequently reported drugs, with 559 and 58 reports, respectively. Through disproportionality analysis, we identified 34 drugs significantly associated with AEs of LABD, including antibiotics, antifungal medications, analgesics, nonsteroidal anti-inflammatory drugs, cardiovascular medications, and calcium channel blockers, among which the antibiotic Vancomycin showed the highest association. These results emphasize the need for further clinical attention to the safety of specific medications.ConclusionThis is the first real-world study using the FAERS database to investigate drug-induced LABD. LABD is closely associated with antibiotic medications. Close monitoring of patients is required when these medications are used clinically to promptly detect and manage potential AEs such as LABD.https://www.frontiersin.org/articles/10.3389/fmed.2025.1521697/fulllinear IgA bullous dermatosisdrug-induced linear IgA bullous dermatosisadverse eventFAERSpharmacovigilance study
spellingShingle Yixuan Yang
Hanzhang Xie
Shuhan Liu
Ying Jia
Bingnan Cui
Zhanshuo Xiao
Linear IgA bullous dermatosis secondary to drugs: a real-world pharmacovigilance study of the FDA adverse event reporting system
Frontiers in Medicine
linear IgA bullous dermatosis
drug-induced linear IgA bullous dermatosis
adverse event
FAERS
pharmacovigilance study
title Linear IgA bullous dermatosis secondary to drugs: a real-world pharmacovigilance study of the FDA adverse event reporting system
title_full Linear IgA bullous dermatosis secondary to drugs: a real-world pharmacovigilance study of the FDA adverse event reporting system
title_fullStr Linear IgA bullous dermatosis secondary to drugs: a real-world pharmacovigilance study of the FDA adverse event reporting system
title_full_unstemmed Linear IgA bullous dermatosis secondary to drugs: a real-world pharmacovigilance study of the FDA adverse event reporting system
title_short Linear IgA bullous dermatosis secondary to drugs: a real-world pharmacovigilance study of the FDA adverse event reporting system
title_sort linear iga bullous dermatosis secondary to drugs a real world pharmacovigilance study of the fda adverse event reporting system
topic linear IgA bullous dermatosis
drug-induced linear IgA bullous dermatosis
adverse event
FAERS
pharmacovigilance study
url https://www.frontiersin.org/articles/10.3389/fmed.2025.1521697/full
work_keys_str_mv AT yixuanyang linearigabullousdermatosissecondarytodrugsarealworldpharmacovigilancestudyofthefdaadverseeventreportingsystem
AT hanzhangxie linearigabullousdermatosissecondarytodrugsarealworldpharmacovigilancestudyofthefdaadverseeventreportingsystem
AT shuhanliu linearigabullousdermatosissecondarytodrugsarealworldpharmacovigilancestudyofthefdaadverseeventreportingsystem
AT yingjia linearigabullousdermatosissecondarytodrugsarealworldpharmacovigilancestudyofthefdaadverseeventreportingsystem
AT bingnancui linearigabullousdermatosissecondarytodrugsarealworldpharmacovigilancestudyofthefdaadverseeventreportingsystem
AT zhanshuoxiao linearigabullousdermatosissecondarytodrugsarealworldpharmacovigilancestudyofthefdaadverseeventreportingsystem